As measles cases mount, new report highlights safety of early vaccination for infants
As Americans prepare for holiday travel amid a nationwide measles resurgence and diminished federal public health communications, a new report from the Center for Infectious Disease Research and Policy's (CIDRAP's) Vaccine Integrity Project (VIP) at the University of Minnesota highlights data showing that infants as young as 6 months can safely receive the measles, mumps and rubella (MMR) vaccine.
As measles cases surge across the United States, an alarming new report from the Center for Infectious Disease Research and Policy highlights the safety and effectiveness of early vaccination for infants. In a worrying development, the Pan American Health Organization has officially revoked the U.S.'s measles elimination status after more than 26 years of success. This means the virus has been spreading continuously for at least a year.
Routine MMR vaccination, which begins at 12 to 15 months, is the standard recommendation for most infants. However, for those who will travel internationally or reside in areas with active measles outbreaks, health authorities have long advocated for an early vaccination, known as the "zero dose" for infants aged 6 to 11 months. The recent report, conducted by the Vaccine Integrity Project (VIP) at the University of Minnesota, emphasizes the importance of this recommendation now more than ever.
Dr. Michael T. Osterholm, director of CIDRAP, explains that the risk of measles exposure in the U.S. has changed significantly. As the holiday travel season approaches, more families with young infants may find themselves in areas where measles is circulating, a situation that was previously rare. The VIP data assessment found that the zero dose provides meaningful protection for infants, with an 83% effectiveness when given between 9 and 11 months, and 58% effectiveness before 9 months.
The assessment also found that the MMR vaccine is safe, with no increased risk of adverse events compared to vaccination at older ages. An important study from Denmark involving 6,540 infants showed no higher rates of adverse reactions in those vaccinated between 5 and 7 months compared to those receiving the vaccine later. Another review of 15 safety studies found no difference in adverse events between early and later vaccination.
However, the report notes that the immune response to vaccination before 12 months may be less durable than the response to later vaccination. Therefore, infants who receive a zero dose should still complete the recommended two-dose MMR series beginning at 12 to 15 months. Parents should be aware that the vaccine can cause a fever, which may occasionally lead to febrile seizures, but this risk is very low and similar for infants and older children.
Despite federal health agencies typically leading vaccine communication, the CDC has been largely silent during this measles outbreak, with its Twitter account largely inactive. This lack of clear communication may contribute to a perception that the issue is unimportant, potentially discouraging parents and healthcare providers from taking the necessary precautions.
Dr. Heidi Moline, CIDRAP clinical adviser and co-author of the paper, advises parents and healthcare providers to ensure they are well-informed about the zero dose to protect infants from this highly infectious virus. As families prepare for the holiday season, protecting young children from measles should be a top priority.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.